SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-041014
Filing Date
2024-05-09
Accepted
2024-05-09 06:23:10
Documents
59
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0205058-10q_cadrenal.htm   iXBRL 10-Q 436854
2 CERTIFICATION ea020505801ex31-1_cadrenal.htm EX-31.1 11961
3 CERTIFICATION ea020505801ex31-2_cadrenal.htm EX-31.2 12202
4 CERTIFICATION ea020505801ex32-1_cadrenal.htm EX-32.1 4701
5 CERTIFICATION ea020505801ex32-2_cadrenal.htm EX-32.2 4847
  Complete submission text file 0001213900-24-041014.txt   3610355

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cvkd-20240331.xsd EX-101.SCH 35780
7 XBRL CALCULATION FILE cvkd-20240331_cal.xml EX-101.CAL 25925
8 XBRL DEFINITION FILE cvkd-20240331_def.xml EX-101.DEF 182532
9 XBRL LABEL FILE cvkd-20240331_lab.xml EX-101.LAB 335310
10 XBRL PRESENTATION FILE cvkd-20240331_pre.xml EX-101.PRE 183561
63 EXTRACTED XBRL INSTANCE DOCUMENT ea0205058-10q_cadrenal_htm.xml XML 336898
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

IRS No.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41596 | Film No.: 24928389
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)